Molly Henderson

CIK 1363812 · CFO and CBO · last filed 2025-04-08

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.00M

Companies

6

Total Filings

51

Lifetime Open-Market Net

-$429.5K

Filer Profile

Reported Address
305 COLLEGE ROAD EAST
PRINCETON, NJ 08540
Related Filers
WARREN D BAGATELLE — 1 joint filings, latest 2006-05-30
Colby Chandler — 1 joint filings, latest 2006-05-30
ROBERT G KLIMASEWSKI — 1 joint filings, latest 2006-05-30
Charles E Phelps — 1 joint filings, latest 2006-05-30
TERENCE A WALTS — 1 joint filings, latest 2006-05-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PHAT CFO and CBO 91,779 $8.37 $768.2K -$447.0K 22 2025-04-08
URGN Chief Financial Officer 5,579 $42.24 $235.7K $6.0K 6 2022-02-02
Ayala Pharmaceuticals, Inc. (ADXS) Delisted Executive Vice President & CFO 73 $0.60 $44 $0 5 2020-05-05
Ayala Pharmaceuticals, Inc. (ADXSW) Delisted Executive Vice President & CFO 5,000 $0 2 2018-06-13
IOVANCE BIOTHERAPEUTICS, INC. (LBIO) Delisted CFO $0 4 2016-06-15
VirtualScopics, Inc. (VSCP) Delisted Chief Business/Financial Off. 1,440 $11.6K 12 2013-02-11

Recent Filings · Page 3 of 6

51 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-05-16 PHAT Buy (P) +6,000 $0 EDGAR
2022-04-06 PHAT Grant (A) +20,000 $0 EDGAR
2022-02-02 URGN Mixed +335 -$2.5K EDGAR
2021-12-02 URGN Mixed +2,413 -$31.1K EDGAR
2021-06-08 URGN Grant (A) $0 EDGAR
2021-05-18 URGN Buy (P) +2,500 $39.6K EDGAR
2021-02-02 URGN Grant (A) $0 EDGAR
2020-10-05 URGN Grant (A) $0 EDGAR
2020-05-05 Ayala Pharmaceuticals, Inc. (ADXS) Delisted Grant (A) $0 EDGAR
2019-10-25 Ayala Pharmaceuticals, Inc. (ADXS) Delisted Grant (A) $0 EDGAR
Showing 2130 of 51
Page 3 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.